Back to company

AMPLEXA GENETICS A/S: Financial statements 2022

CVR: 29428441

AMPLEXA GENETICS A/S (CVR 29428441) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 5,494,691 and a net result of DKK -2,282,128 compared with DKK 12,328,350 the year before. That is a decrease of 72.9% compared with the year before. Equity amounted to DKK -14,490,612. The company had 14 employees in the financial year.

Gross Profit
5,494,691 kr.
Profit/Loss
-2,282,128 kr.
Equity
-14,490,612 kr.
Total Assets
12,283,953 kr.
Employees
14

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-5.5 mio.-2.3 mio.-14.5 mio.14
2021-20.3 mio.12.3 mio.-12.2 mio.13
2020-12.4 mio.5.9 mio.-24.5 mio.7
2019-2.8 mio.-1.5 mio.-30.4 mio.7
2018-907 t.-3.7 mio.-28.9 mio.7

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on AMPLEXA GENETICS A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

AMPLEXA GENETICS A/S: The 2021 annual report is outMay 12, 2022

AMPLEXA GENETICS A/S has published its annual report for 2021. Gross profit came to DKK 20,278,070, and the net result was DKK 12,328,350.

About AMPLEXA GENETICS A/S

AMPLEXA GENETICS A/S is a Danish company of the type Aktieselskab based in Odense C, founded in 2006. The company is registered under the industry Anden teknisk rådgivning. The management consists of Hans Atli Eli Albinus Dahl. The company is owned by SCIENT. INVEST ApS, Conseco P/F and Sp/f D65 Holding. The company has 9 employees. In 2025, the company reported a gross profit of DKK 4,009,035 and a net result of DKK -1,583,233 compared with DKK -11,108,344 the year before. Equity amounted to DKK -10,313,267.